Toxicological Research

Korean Society of Toxicology & Korea Environmental Mutagen Society (한국독성학회)
권호 표지
DOI QR코드

DOI QR Code

Toxicity Screening After Single Dose of a Newly Developed Oral Heparin Derivative in Male Cynomolgus Monkeys

게잡이 원숭이에 있어 새로운 헤파린유도체의 단회투여 독성스크리닝

  • Kim, Choong-Yong (Non-Human Primate Team, Toxicology Division, Korea Institute of Toxicology, KRICT) ;
  • Kim, Sang-Kyoon (Department of Materials Science and Engineering, Gwangju Institute of Science and Technology) ;
  • Woo, Young-Ah (Non-Human Primate Team, Toxicology Division, Korea Institute of Toxicology, KRICT) ;
  • Jeong, Eun-Ju (Non-Human Primate Team, Toxicology Division, Korea Institute of Toxicology, KRICT) ;
  • Han, Su-Cheol (Non-Human Primate Team, Toxicology Division, Korea Institute of Toxicology, KRICT) ;
  • Heo, Jeong-Doo (Non-Human Primate Team, Toxicology Division, Korea Institute of Toxicology, KRICT) ;
  • Park, Kui-Lea (National Institute of Toxicological Research) ;
  • Byun, Young-Ro (College of Pharmacy, Seoul National University)
  • 김충용 (한국화학연구원 안정성평가연구소) ;
  • 김상균 (광주과학기술원) ;
  • 우영아 (한국화학연구원 안정성평가연구소) ;
  • 정은주 (한국화학연구원 안정성평가연구소) ;
  • 한수철 (한국화학연구원 안정성평가연구소) ;
  • 허정두 (한국화학연구원 안정성평가연구소) ;
  • 박귀례 (국립독성연구원) ;
  • 변영로 (서울대학교 약학대학)
  • Published : 2007.06.30
Download PDF
⟨ Previous Next ⟩

Abstract

Toxicity screening of a newly developed oral heparin derivative were carried out in 6 male cynomolgus monkeys (Macaca fascicularis), composed of a treatment group and vehicle control group. A newly orally active heparin derivative, developed by Seoul National University, was once given to treatment group at dose of 500 mg/kg. A treatment group did not show any change in body weights, hematological parameters including platelet-related varivables (platelet, PDW, PCT, MPV) and serum biochemical parameters (e.g., AST, ALT, BUN, etc.) for 2 weeks compared with those of vehicle control group. We also confirmed the maximum plasma concentration (Cmax, 1.73 IU/ml) and the time (Tmax, 1 hr) to reach Cmax. The present study will be valuable in the proper interpretation for nonclinical study using cynomolgus monkeys in the development of new drug of heparin derivative.

Keywords

References

  1. Aken, H.V., Bode, C.B., Darius, H., Diehm, C., Encke, A., Gulba, D.C., Haas, S., Haccke, W., Puhl, W., Quante, M., Riess, H., Scharf, R., Schellong, S., Schror, K., Schulte, K.-L. and Tebbe, U. (2001). Anticoagulation: The present and future. Clin. Appl. Thrombo. Hemost., 7, 195-204 https://doi.org/10.1177/107602960100700303
  2. Alpert, J.S. and Dalen, J.E. (1994). Epidemiology and natural history of venous thromboembolism. Prog. Cardiovasc. Dis., 36, 417-422 https://doi.org/10.1016/S0033-0620(94)80050-2
  3. Cines, D.B., Rauova, L., Arepally, G., Reilly, M.P., McKenzie, S.E., Sachais, B.S. and Poncz, M. (2007). Heparininduced thrombocytopenia: an autoimmune disorder regulated through dynamic autoantigen assembly/disassembly. J. Clin. Apher., 22, 31-36 https://doi.org/10.1002/jca.20109
  4. Gonze, M.D., Salartash, K., Sternbergh III, W.C., Baughman R.A., Leone-Bay, A. and Money, S.R. (2000). Orally administered unfractionated heparin with carrier agent is therapeutic for deep venous thrombosis. Circulation, 101, 2658-2661 https://doi.org/10.1161/01.CIR.101.22.2658
  5. Ginsberg, J.S. (1999). Thromboembolism and pregnancy. Thromb. Haemost., 82, 620-625 https://doi.org/10.1055/s-0037-1615888
  6. Hirsh, J. and Fuster, V. (1994). Guide to anticoagulant therapy, Part 1: heparin. Circulation, 89, 14449-1468
  7. Hirsh, J. (2003). Current anticoagulant therapy-unmet clinical needs. Throm. Res., 109, S1-S8 https://doi.org/10.1016/S0049-3848(03)00250-0
  8. Hull, R., Delmore, T., Carter, C., Hirsh, J., Genton, E., Gent, M., Turpie, G. and McLaughlin, D. (1982). Adjusted subcutaneous heparin versus warfarin sodium in the longterm treatment of venous thrombosis. N. Engl. J. Med., 306, 189-194 https://doi.org/10.1056/NEJM198201283060401
  9. Kim, S.K., Vaishali, B., Lee, E., Lee, S., Lee, Y.K., Kumar, T.S., Moon, H.T. and Byun, Y. (2006). Oral delivery of chemical conjugates of heparin and deoxycholic acid in aqueous formulation. Thromb. Res., 117, 419-427 https://doi.org/10.1016/j.thromres.2005.03.027
  10. Lee, Y., Moon, H.T. and Byun, Y. (1998). Preparation of slightly hydrophobic heparin derivatives which can be used for solvent casting in polymeric formulation. Thromb. Res., 92, 149-156 https://doi.org/10.1016/S0049-3848(98)00124-8
  11. Lee, Y., Nam, J.H., Shin, H.C. and Byun, Y. (2001). Conjugation of low-molecular-weight heparin and deoxycholic acid for the development of a new oral anticoagulant agent. Circulation, 104, 3116-3120 https://doi.org/10.1161/hc5001.100627
  12. Lee, Y.K., Kim, S.K., Lee, D.Y., Lee, S., Kim, C.Y., Shin, H.C. and Moon, H.T. (2006). Efficacy of orally active chemical conjugate of low molecular weight heparin and deoxycholic acid in rats, mice and monkeys. J. Control Release, 111, 290-298 https://doi.org/10.1016/j.jconrel.2005.12.011
  13. Malkov, D., Wang, H., Dinh, S., Steven, D. and Gomez-Orellana, I. (2002). Pathway of oral absorption of heparin with sodium N-(8-(2 hydroxybenzoyl)amino) caprylate. Pharm. Res.. 19, 1180-1184 https://doi.org/10.1023/A:1019802310702
  14. Mark, D.G., Jeffrey, D.M. and Andrea, L.B. (1998). Orally administered heparin for preventing deep venous thrombosis. Am. J. Surg., 176, 176-178
  15. Menajovsky, L.B. (2005). Heparin-induced thrombocytopenia: clinical manifestations and management. Am. J. Med., 118(Suppl. 8A), 21S-30S
  16. Strandness, D.E. Jr. (2001). Anticoagulant therapy: Current status and shortcomings. Seminars in Interventional Radiology, 18, 113-118
  17. Wolford, S.T., Schroer, R.A., Gohs, F.X., Gallo, P.P., Brodeck, M., Falk, H.B. and Ruhren, R.R. (1986). Reference range data base for serum chemistry and hematology values in laboratory animals. J. Toxicol. Environ. Heal., 18, 161- 188 https://doi.org/10.1080/15287398609530859
  18. 김충용, 이현숙, 한수철, 허정두, 하창수, 권명상, 정문구 (2004). Cynomolgus monkey에 있어 혈액학 및 혈액생화학적 지표. 한국실험동물학회지, 20, 44-48
  19. 정영미 (2006). 항응고제치료에 사용되는 약물. 병원약사회지, 23, 5-11